Literature DB >> 15494696

Antitumor reactivity of splenocytes primed in vivo with dendritic-cell-based vaccine and secondarily activated with a cocktail of cytokines in vitro.

Sheng Zhang1, Wen-Feng Li, Hong-Jun Zhang, Qin Wang.   

Abstract

AIM: To evaluate the antitumor reactivity of splenocytes primed in vivo with dendritic cell (DC) based vaccine and secondarily activated with cocktail of cytokines in vitro.
METHODS: Tumor lysate pulsed DC were used to generate effector T cells in the murine L615 leukemia model. DC were induced and pulsed with tumor lysate. The splenocytes from the DC based vaccine primed mice were termed VPS. Some VPS were activated with anti-CD3 alone (VPS-CD3), the other cells were activated with a cocktail of cytokines including IFN-gamma, IL-1beta, anti-CD3 and IL-2 (VPSC).
RESULTS: Both VPS and VPS-CD3 showed moderate IFN-gamma release to stimulatory tomor cells in vitro and antitumor capacity in vivo. However, VPSC showed much higher IFN-gamma release and far superior antitumor capacity than the other cells in this leukemia model.
CONCLUSION: The result here indicates that tumor lysate pulsed DC can be used as a strategy to generate effector T cells which can be further activated with a cocktail of cytokines for adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494696

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  1 in total

1.  A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.

Authors:  Ekaterina A Alyamkina; Valeriy P Nikolin; Nelly A Popova; Evgenia V Dolgova; Anastasia S Proskurina; Konstantin E Orishchenko; Yaroslav R Efremov; Elena R Chernykh; Alexandr A Ostanin; Sergey V Sidorov; Dmitriy M Ponomarenko; Stanislav N Zagrebelniy; Sergey S Bogachev; Mikhail A Shurdov
Journal:  Genet Vaccines Ther       Date:  2010-11-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.